Amir Arain, MD
Neurology · Salt Lake City, UTNPI 1992810709
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $230,520 of the $328,830 with a category attached, or 70.1%. 17 manufacturers reported payments, led by SK Life Science, Inc. at 37.9% of the total. Among neurology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $784.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$125K
- Neurelis, Inc.$77K
- UCB, Inc.$75K
- Sunovion Pharmaceuticals Inc.$23K
- Eisai Inc.$20K
- Neuropace, Inc.$3K
- plus $7K from 11 others
Across 8 payments — averaging $9056.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$35K
- SK Life Science, Inc.$33K
- Medtronic$4K
- UCB SA$142
What the payments were for
- Consulting fees$50,90915%
- Speaking & faculty fees$230,52070%
- Travel & lodging$36,22311%
- Food & beverage$11,1153%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 134 | $124,767 |
| Neurelis, Inc. | 83 | $77,347 |
| UCB, Inc. | 111 | $74,664 |
| Sunovion Pharmaceuticals Inc. | 32 | $22,960 |
| Eisai Inc. | 25 | $19,628 |
| Neuropace, Inc. | 6 | $2,829 |
| Catalyst Pharmaceuticals, Inc. | 4 | $1,730 |
| UCB SA | 9 | $1,229 |
| Aprecia Pharmaceuticals, LLC | 1 | $1,160 |
| DIXI Medical USA Corp | 2 | $927 |
| Vertex | 1 | $517 |
| Livanova USA, Inc. | 4 | $503 |
| Medtronic | 1 | $178 |
| Biocodex, Inc. | 2 | $132 |
| Jazz Pharmaceuticals Inc. | 2 | $127 |
| Greenwich Biosciences, Inc. | 1 | $85 |
| Zogenix Inc. | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$94,376
- VALTOCO$65,180
- Briviact$25,447
- Cenobamate$24,748
- APTIOM$22,707
- Fycompa$21,034
- Fintepla$17,404
- Nayzilam$8,442
- RNS System$1,887
- Spritam$1,160
- RNS Neurostimulator Kit$943
- VNS Therapy$336
- ACTIVA$178
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$115
How this compares
$328,830 in reported general payments places this provider in the 95th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 363 | $486,525 |
| EpidiolexCannabidiol (Cbd) | 48 | $205,033 |
| Vigabatrin | 12 | $177,359 |
| AptiomEslicarbazepine Acetate | 47 | $74,515 |
| FycompaPerampanel | 54 | $59,500 |
| VimpatLacosamide | 15 | $33,249 |
| BriviactBrivaracetam | 20 | $31,176 |
| Lacosamide | 134 | $15,327 |
| Lamotrigine ErLamotrigine | 28 | $14,036 |
| Clobazam | 119 | $12,100 |
| KeppraLevetiracetam | 16 | $11,041 |
| Lamotrigine | 389 | $10,334 |
| Divalproex Sodium | 62 | $7,398 |
| Zonisamide | 183 | $6,078 |
| Levetiracetam | 186 | $5,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $124,767 | $486,525363 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $22,960 | $74,51547 claims |
| UCB, Inc.Vimpat, Briviact | $74,664 | $64,42635 claims |
| Eisai Inc.Fycompa | $19,628 | $59,50054 claims |
| UCB SAKeppra | $1,229 | $11,04116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 157 neurology providers in Utah.
Other neurology in Salt Lake City
- Timothy WestSalt Lake City$856K
- Stacey SteevesSalt Lake City$548K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Lucy DewittSalt Lake City$81K
- Nicholas JohnsonSalt Lake City$80K
- Viktoria KaplanSalt Lake City$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.